T1	Participants 119 152	patients with chronic hepatitis C
T2	Participants 484 589	1,046 patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial
T3	Participants 591 704	All patients had failed prior treatment with IFN or peginterferon +/- RBV and had Ishak fibrosis scores > or = 3.
